Andrew Denver

Andrew Denver

Non-Executive Director

Mr Denver has extensive expertise that is relevant to QBiotics Group, including assisting in the commercialisation of several technology companies. Mr Denver has wide ranging knowledge of the life sciences industry of which QBiotics Group is a part including, risk assessment, financial reporting and general management, which are important in the success of QBiotics Group’s business. Mr Denver was the interim Chief Executive Officer of Universal Biosensors, Inc. (UBI) from September 2010 to May 2011, a director of UBI from December 2002 to August 2017 and Chairman of UBI from September 2005 to August 2017. Between 2002 and 2005, Mr Denver was President of Pall Asia, a subsidiary of Pall Corporation after the acquisition by Pall Corporation of US Filter’s Filtration and Separations business, where he was also President. Pall Corporation is a technology-based filtration, separation and purification multinational company.

Mr Denver is a non-executive director of Vaxxas, Inc., SpeeDx Pty Ltd and Cochlear Limited, all of which are life sciences companies.

Mr Denver graduated from the University of Manchester with a Bachelor of Science Degree (Honours) in Chemistry and achieved a distinction in his MBA at the Harvard Business School and is a Fellow of the Australian Institute of Company Directors.

Mr Denver was previously a director of QBiotics and was appointed as a director of QBiotics Group on 1 November 2017.